APOA1 and Hypoglycemia: A proof-of-concept study with a recombinant fusion protein insulin coupled to apolipoprotein A-I (Ins-ApoAI) apolipoprotein A-I (Apo) confirmed a slow but prolonged mechanism of action, which diminishes the risk of hypoglycemia [49].